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provided it is propeObjective: Several pieces of evidence indicate that HIV-infected adults undergo
premature aging. The effect of HIV and antiretroviral therapy (ART) exposure on the
aging process of HIV-infected children may be more deleterious since their immune
system coevolves from birth with HIV.
Design: Seventy-one HIV-infected (HIVþ), 65 HIV-exposed-uninfected (HEU), and 56
HIV-unexposed-uninfected (HUU) children, all aged 0–5 years, were studied for
biological aging and immune senescence.
Methods: Telomere length and T-cell receptor rearrangement excision circle levels
were quantified in peripheral blood cells by real-time PCR. CD4þ and CD8þ cells were
analysed for differentiation, senescence, and activation/exhaustion markers by flow
cytometry.
Results: Telomere lengths were significantly shorter in HIVþ than in HEU and HUU
children (overall, P<0.001 adjusted for age); HIVþ ART-naive (42%) children had
shorter telomere length compared with children on ART (P¼0.003 adjusted for age).
T-cell receptor rearrangement excision circle levels and CD8þ recent thymic emigrant
cells (CD45RAþCD31þ) were significantly lower in the HIVþ than in control groups
(overall, P¼0.025 and P¼0.005, respectively). Percentages of senescent
(CD28CD57þ), activated (CD38þHLA-DRþ), and exhausted (PD1þ) CD8þ cells were
significantly higher in HIVþ than in HEU and HUU children (P¼0.004, P<0.001, and
P<0.001, respectively). Within the CD4þ cell subset, the percentage of senescent cells
did not differ between HIVþ and controls, but programmed cell death receptor-1
expression was upregulated in the former.
Conclusions: HIV-infected children exhibit premature biological aging with acceler-
ated immune senescence, which particularly affects the CD8þ cell subset. HIV infection
per se seems to influence the aging process, rather than exposure to ART for prophylaxis
or treatment. Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2016, 30:1363–1373Keywords: immune activation, immune senescence, microbial translocation,
pediatric HIV/AIDS, premature aging, telomere length, T-cell receptor
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The introduction of antiretroviral therapy (ART) has
changed the natural history of pediatric HIV infection;
ART-based prophylaxis regimens have in fact reduced
mother-to-child transmission of HIV from 15–20% to
under 2% in high-income countries, and have also given
rise to substantial improvements in terms of survival and
quality of life in HIV-infected children [1,2]. HIV
infection is, therefore, now considered a chronic disease
which persists for many decades [3]. However, despite
improvements in immune function and reduction of
AIDS-related complications, including opportunistic
infections and AIDS-associated malignancies, ART does
not restore full health. Many studies have demonstrated
that ART-treated HIV-infected adults have a higher risk
of non-AIDS-related overall morbidity and mortality
compared with age-matched HIV-uninfected individuals.
This increased risk is mainly because of a range of non-
AIDS-defining illnesses associated with aging, including
malignancies [4–8], and it has been advanced that the
increase in non-AIDS-defining diseases among HIV-
infected patients may be because of premature aging [9].
The pathogenic mechanism underlying this increased risk
is still poorly understood. Chronic immune activation
because of the persistence of circulating HIV virions may
play a key role in the senescent pathway. Activated cells
undergo clonal expansion in response to viral persistence,
resulting in differentiation and accumulation of non-
functional senescent cells [10]. It has been also advanced
that premature and accelerated aging in HIV-infected
patients can be because of adverse effects of antiretroviral
drugs. Nucleoside reverse transcriptase inhibitors have
been shown to inhibit telomerase activity in replicating
cell lines in vitro, leading to accelerated shortening of
telomere length [11,12].
The clinical complications of HIV infection and ART
treatment in children may be more serious than in adults.
The course of vertically transmitted infection in infants is
characterized by faster disease progression and shorter
time to AIDS, compared with adults. After infection,
plasma HIV-RNA levels are higher in infants than in
adults. In addition, they persist at high levels and decline
slowly with age in the absence of ART [13,14], whereas
in adults control of viral load is reached a few weeks after
infection [15]. This slower control of viral replication is
probably because of the fact that the immune system is still
maturing. The innate immunity in children is of
particular importance and plays a critical role in HIV
pathogenesis [16–18], as the adaptive immune system is
still developing [19]. HIV infection since birth together
with long-term exposure to ART may affect premature
aging and immune senescence in HIV-infected children
even more than in adults.
To date, few data are available on premature aging in
HIV-infected children [20–23] and no reports give a Copyright © 2016 Wolters Kluwer Hcomprehensive assessment of telomere shortening, a key
molecular marker of biological aging, together with the
activation/senescent profile of T lymphocytes. In this
study, we analysed biological aging in relation to immune
activation and senescence markers in a cohort of
perinatally HIV-infected children.Methods
Ethic statement
The study was approved by the Ethics Committees of the
Azienda Ospedaliera Padova (Prot. n.#2921P) and the
Hospital Sant Joan de De´u, Universitat de Barcelona
(Prot. n.#04–15); written informed consent was
obtained for all children from their parents/guardians.
Study population
A total of 71 perinatally HIV-infected (HIVþ), 65 HIV-
exposed-uninfected (HEU), and 56 HIV-unexposed-
uninfected (HUU) children, all aged 0–5 years, were
included in this study. HIVþand HEU children attended
the Department of Mother and Child Health, University
of Padova or the Infectious Diseases Unit, Pediatrics
Department, Hospital Sant Joan de De´u, Universitat de
Barcelona. For each HIVþ and HEU child, the first
cryopreserved sample available after birth was chosen for
the study. None of the HIVþ or HEU children was
breastfed. HUU children were recruited at Pediatric
Emergency Department of Azienda Ospedaliera Padova
or Hospital Sant Joan de De´u, Universitat de Barcelona.
Exclusion criteria were malignancies, chronic infections,
sarcoidosis, diabetes mellitus type-1, rheumatoid arthritis,
and systemic lupus erythematosus.
Sample preparation
Peripheral blood mononuclear cells (PBMC) were
isolated from ethylenediaminetetraacetic acid-treated
peripheral blood (2–5 ml) by centrifugation on a
Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden).
PBMC were cryopreserved and plasma samples were
stored in liquid nitrogen and at 808C, until use.
Telomere length measurement by quantitative
real-time PCR
Relative telomere length was determined by mono-
chrome quantitative multiplex PCR assay [24] with
minor modifications. Each PCR reaction was performed
in a final volume of 25ml containing 5ml sample
(2 ng DNA/ml) and 20ml reaction mix containing
0.75 SYBR GreenI (Invitrogen, Italy), 10 mmol/l
Tris-hydrochloric acid pH 8.3, 50 mmol/l potassium
chloride, 3 mmol/l magnesium chloride, 0.2 mmol/l
each deoxynucleotide (dNTP) (Applied Biosystems,
Foster City, California, USA), 1 mmol/l dithiothreitol,
0.625 U AmpliTaq Gold DNA polymerase, 1% dimethyl
sulfoxide (Sigma-Aldrich, St Louis, Missouri, USA), andealth, Inc. All rights reserved.
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albumin gene primers sequences are described in [24].
PCR reactions were performed on a LightCycler480
real-time PCR detection system (Roche Applied
Science, Mannheim, Germany). The thermal cycling
profile was 15 min at 958C, two cycles of 15 s at 948C, 15 s
at 498C, followed by 40 cycles of 15 s at 948C, 10 s
at 628C, 15 s at 748C, 10 s at 848C, 15 s at 888C, with
signal acquisition at the end of both the 748C and 888C
steps. A standard curve was generated at each PCR run,
consisting of DNA from the RAJI cell line, serially
diluted from 100 to 0.41 ng/ml [25]. LightCycler raw
text files were converted using the LC480Conversion
free software (http://www.hartfaalcentrum.nl/index.
php?main¼files&fileName¼ LC480Conversion.zip&de
scription¼LC480%20Conversion&sub¼LC480Convers
ion), and the data were analysed using LinRegPCR free
software [26]. All samples were blindly and consecutively
run in triplicate together with reference samples. The
intra and interassay reproducibility of both telomere and
albumin PCR results was evaluated using dilutions of the
reference curve. Telomere length values were calculated
as telomere/single-copy gene (T/S) ratio, as previously
described [25]. The intra and interassay variability of
T/S values was evaluated using reference samples;
coefficients of variation were 3.98% or less and 8.14%
or less, respectively.
T-cell receptor rearrangement excision circle
levels quantification
Thymic output in PBMC was studied by measurement of
T-cell receptor rearrangement excision circle (TREC)
levels by real-time PCR, as previously described [27].
TREC levels were expressed as the number of TREC
copies/105 PBMC.
Viral load quantification
Plasma HIV-RNA levels were determined in all HIV-
infected children using the COBAS Taqman HIV-1 test
(Roche, Branchburg, New Jersey, USA). The lower limit
of detection was 50 HIV-RNA copies/ml. HIV-DNA
levels in PBMC were measured by real-time PCR, and
expressed as HIV-DNA copies/106 PBMC as previously
described [27].
Flow cytometry analysis
T-cell phenotyping was performed on cryopreserved
PBMC. Cells were thawed, washed, stained for 20 min in
the dark with the Live/Dead Fixable Near-IR Dead
Cell Stain Kit (Life Technologies, Carlsbad, California,
USA) and with fluorescent-conjugated mononuclear
antibodies CD3-fluorescein isothiocyanate, CD31-
phycoerythrin (PE), CD38-PE, CD57-PE, CD45RA-
allophycocyanin (APC) and programmed cell death
receptor (PD)-1-PECy7 (Becton-Dickinson, San Diego,
California, USA), CD27-PECy7 (Beckman Coulter,
Fullerton, California, USA) and CD4-VioBlue,
CD8-VioGreen, Human Leukocyte Antigen - antigen Copyright © 2016 Wolters KluweD Related (HLA-DR)-APC, and CD28-APC (Miltenyi
Biotec, Auburn, California, USA). Appropriate isotypic
controls (mouse IgG1-PE, IgG2b-APC, and IgG1k-
PECy7) were used to evaluate nonspecific staining. Cells
were then washed and resuspended in phosphate-
buffered saline supplemented with 1% paraformalde-
hyde. All samples were analysed using LSRII Flow
cytometer (Becton-Dickinson). A total of 100 000 events
were collected in the lymphocyte gate using morpho-
logical parameters (forward and side-scatter). Data were
processed with FACSDivaSoftware (Becton-Dickinson)
and analysed using KaluzaAnalyzing Software v.1.2
(Beckman Coulter) (Supplementary Figure 1, http://
links.lww.com/QAD/A903). Samples for flow-cytome-
try analysis were available for 24 HIVþ children, 21
HEU, and 18 HUU children. The characteristics of
these subgroups are given in Supplementary Table 1,
http://links.lww.com/QAD/A904.
Quantification of soluble markers
Plasma levels of soluble CD14 (sCD14), IL-6, and TNFa
were quantified with commercially available assays
(Human sCD14, IL-6, and TNFa Quantikine ELI-SA;
R&D Systems, Minneapolis, Minnesota, USA) according
to the manufacturer’s protocol. Samples for analysis of
soluble markers were available for 24 HIVþ, 21 HEU, and
18 HUU children.
Statistical analysis
Unadjusted comparisons of continuous variable distri-
butions among groups were assessed with the Kruskal–
Wallis nonparametric test, and the associations
between categorical variables were analysed by the
x2 test. Spearman’s r coefficient (rs) was used for
correlations. Normal distributions for telomere
length and TREC levels were visually checked by
quantile–quantile plots. Linear regression models esti-
mated the telomere length and TREC levels in HIVþ,
HEU, and HUU children, ART exposure and naive
groups, log-transformed HIV-RNA and HIV-DNA
covariates, adjusted for age and its interaction with
groups. Samples with undetectable plasma HIV-RNA
were assigned a value of 20 copies/ml to include them in
the statistical analyses. All statistical analyses were
performed with Statistical Analysis Software (SAS)
(Release 9.2; SAS Institute, Cary, North Carolina,
USA). Adjustments for multiple testing with Hochberg’s
correction were made for comparisons of CD4þ and
CD8þ cell subsets among groups. All P values were two-
tailed, and were considered significant at less than 0.05.Results
Characteristics of study population
The characteristics of the study population are listed in
Table 1. The median age of HIVþ children was 3.11r Health, Inc. All rights reserved.
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for HEU, and 1.85 (0.85–3.46) years for HUU children.
Thirty of the 71 (42%) HIVþ children were ART-naive,
the others were on ART [median time 18 (11–36.5)
months]. ART-naive HIVþ children were younger than
those on therapy [1.70 (0.69–3.59) and 3.62 (2.17–4.81)
years, respectively; P¼ 0.004]. Sixty-one of the 65
(93.8%) HEU children had been exposed to ART
prophylaxis during gestation [median 34 (17–38) weeks]
and received postnatal prophylaxis [6 weeks of zidovudine
(ZDV) monotherapy]. Of the 61 ART-treated pregnant
women, 40 (65.6%) had received triple therapy based on
ZDVþ lamivudine (3TC)þ nevirapine (NVP), 17
(27.8%) ZDVþ 3TCþ protease inhibitor, and the
remaining 4 (6.6%) a regimen based on tenofovir
(TDF)þ emtricitabine (FTC)þ protease inhibitor.
Telomere length is shorter in HIV-infected
children than in controls
The median telomere length value in PBMC was
significantly lower in HIVþ than in HEU and HUU
children, being 2.21 (1.94–2.58), 2.63 (2.25–3.21), and
2.88 (2.49–3.1), respectively [P< 0.001 not age adjusted
(Fig. 1a); P< 0.001 age adjusted]. Telomere length values
significantly decreased with age in HEU and HUU
(regression coefficient (b)¼0.0102, P¼ 0.008 and
b¼0.0100, P¼ 0.011, respectively), but not in HIVþ
children (b¼0.0018, P¼ 0.587) (Fig. 1b). Of note, in
the HIVþ group, ART-naive children had shorter
telomere length compared with those on ART [2.11
(1.75–2.37) ‘vs.’ 2.46 (2.07–2.68); P¼ 0.006 not age
adjusted (Fig. 1c); P¼ 0.003 age adjusted]. Telomere
lengths were not associated with age in either ART-naive
(b¼0.0054, P¼ 0.227) or ART-treated children
(b¼0.0046, P¼ 0.258) (Fig. 1d). After adjusting for
age, mean telomere length values tended to decrease with
increasing HIV-RNA levels (b¼0.0396; P¼ 0.056), Copyright © 2016 Wolters Kluwer H
Table 1. Demographic and clinical characteristics of HIVR, HIV-exposed
HIVþ
Age, median (IQR) years 3.11 (1.
Sex, n (%)
Men 39
Ethnicity/race, n (%)
White 49
Black 20
Asian 2
Exposed to ART prophylaxis, n (%) 5
Exposed to ART, n (%) 41
Duration of ART exposure, median (IQR) months 18 (1
Percentage of lifetime on ART 57.5 (42
Detectable plasmaviremia at sample collection, n (%) 54/71
ART naive 30/30
On ART 17/41
Plasmaviremia at sample collection (log10 copies/ml)
ART naive 5.31 (4.
On ART 3.96 (2.
ART, antiretroviral therapy; HEU, HIV-exposed-uninfected children; HIVþ
IQR, interquartile range.but not with HIV-DNA levels (b¼0.0004, P¼ 0.490),
and were significantly lower in ART-naive children
(b¼0.3913, P¼ 0.003). In the final multivariate
model, including all variables, the stepwise method
selected only ART exposure as a significant predictor
variable of higher mean telomere length value
(P¼ 0.039).
Thymic output is lower in HIV-infected children
than in controls
HEU and HUU children had higher TREC levels than
HIVþ children [5409 (3470–6600), 5370 (2380–8102),
3498 (2051–6780)] TREC copies/105 PBMC, respec-
tively [P¼ 0.018 not age adjusted (Fig. 1e); P¼ 0.025
age-adjusted]. TREC levels decreased significantly with
increasing age in HEU and HUU groups (b¼61,
P¼ 0.009 and b¼86, P¼ 0.001, respectively), but not
in HIVþ children (b¼17, P¼ 0.353) (Fig. 1f). No
significant differences in TREC dynamics were found
between ART-treated and ART-naive children (Fig. 1g
and h).
Phenotypic T-cell alterations occur early in HIV-
infected children
There were no differences in the frequencies of CD3þ
cells among the three groups (P¼ 0.590) (Table 2). The
percentages of total CD4þ cells were lower in the HIVþ
than in the control groups (P¼ 0.001). Within CD4þ
cells, HIVþand control groups did not significantly differ
in percentages of naive (CD45RAþCD27þ), central
memory (CD45RACD27þ), effector memory
(CD45RACD27), and terminally differentiated
(CD45RAþCD27) cell subsets (Table 2). However,
when central and effector memory cell subsets, the major
cellular reservoirs for HIV [28], were considered
together, they tended to be lower in HIVþ than in
HEU and HUU children [21.9 (15.3–38.3)% ‘vs’ 29.8ealth, Inc. All rights reserved.
-uninfected children, and HIV-unexposed-uninfected children.
(n¼71) HEU (n¼65) HUU (n¼56)
40–4.48) 1.74 (0.99–3.31) 1.85 (0.84–3.46)
(55%) 34 (52%) 29 (52%)
(69%) 47 (72.3%) 49 (87.5%)
(28.2%) 15 (23.1%) 5 (9.0%)
(2.8%) 3 (4.6%) 2 (3.5%)
(7%) 61 (93.8%) –
(58%) – –
2–36) – –
.6–84.5) – –
(76.1%) – –
(100%) – –
(58.5%)
90–5.62) – –
70–5.27) – –
, HIV-infected children; HUU, HIV-unexposed-uninfected children;
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
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Fig. 1. HIV-infected (HIVR) children have shorter telomere length (TL) and lower T-cell receptor rearrangement excision circle
(TREC) levels than HIV-exposed-uninfected (HEU) and HIV-unexposed-uninfected (HUU) children. (a) TL values not age-
adjusted in HIVþ (n¼71), HEU (n¼65), and HUU (n¼56) children. (b) TL as function of age in HIVþ (black circles, continuous
line), in HEU (gray squares, continuous line), and HUU (white circles, dotted line) children. (c) TL values not age-adjusted in
HIVþ children, subdivided into antiretroviral therapy (ART)-naive (n¼30) and on ART (n¼41). (d) TL as function of age in HIVþ
children, subdivided into ART-naive (gray squares) and ART-treated (black circles). (e) TREC levels not age-adjusted in HIVþ
(n¼71), HEU (n¼65), and HUU (n¼56) children. (f) TREC levels as function of age in HIVþ (black circles, continuous line), in
HEU (gray squares, continuous line) and HUU (white circles, dotted line) children. (g) TREC levels not age-adjusted among HIVþ
children, subdivided into ART-naive (n¼30) and on ART (n¼41). (h) TREC levels as function of age in HIVþ children, subdivided
into ART-naive (gray squares) and on ART (black circles). Boxes and whiskers: 25–75th and 10–90th percentiles, respectively;
central line in boxes: median. b, regression coefficient.
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Table 2. Frequencies of CD4R and CD8R T-cell subsets.
HIVþ (n¼24) % median (IQR) HEU (n¼21) % median (IQR) HUU (n¼18) % median (IQR) Overall P value
CD3þ 64.4 (58.8–69.2) 61.8 (49.8–68.4) 60.2 (54.6–66.4) 0.590
CD4þ 39.6 (35.1–45.3) 53.4 (43.5–64.7) 52.5 (38.0–60.6) 0.001
Naive 76.8 (59.9–84.4) 70.1 (59.9–81.0) 64.7 (56.9–75.3) 0.423
Central memory 18.1 (13.2–31.1) 27.3 (17.4–32.6) 27.9 (20.7–35.1) 0.206
Effector memory 3.4 (1.2–5.8) 2.5 (1.8–6.3) 4.4 (2.9–7.8) 0.220
T. differentiated 0.5 (0.2–1.0) 0.3 (0.1–0.6) 0.4 (0.3–0.1) 0.330
RTE 63.6 (54.9–72.4) 58.3 (46.0–68.2) 54.2 (49.3–61.7) 0.181
PEC 12.4 (5.3–16.4) 11.7 (8.2–16.1) 10.4 (8.1–15.2) 0.738
Senescent 0.4 (0.1–0.7) 0.2 (0.1–0.5) 0.2 (0.1–1.3) 0.568
Activated 3.3 (2.2–5.9) 2.1 (1.3–3.5) 2.8 (1.6–3.8) 0.041
Exhausted 4.1 (3.4–6.6) 3.5 (1.9–5.2) 3.2 (2.7–5.1) 0.050
CD8þ 31.2 (25.8–39.6) 28.9 (21.2–35.0) 25.9 (22.8–29.0) 0.063
Naive 46.2 (37.6–75.1) 77.1 (55.9–84.7) 71.0 (46.7–86.1) 0.019
Central memory 11.0 (6.9–23.2) 16.3 (10.9–26.5) 12.7 (9.8–18.9) 0.278
Effector memory 7.1 (2.3–13.1) 2.1 (1.1–4.9) 4.3 (1.3–11.4) 0.033
T. differentiated 16.3 (4.5–36.4) 2.5 (1.0–8.6) 4.2 (2.1–16.2) 0.001
RTE 55.3 (41.4–71.8) 69.8 (60.4–80.1) 68.1 (59.5–79.3) 0.005
PEC 17.1 (6.5–29.2) 5.9 (3.8–15.3) 9.8 (4.6–15.2) 0.040
Senescent 25.8 (12.4–43.2) 8.5 (6.8–16.7) 9.7 (3.3–27.3) 0.004
Activated 7.0 (5.2–12.2) 4.7 (3.9–7.6) 3.4 (2.8–6.7) <0.001
Exhausted 7.1 (5.0–12.4) 3.5 (2.1–5.9) 3.7 (2.4–5.3) <0.001
HEU, HIV-exposed-uninfected children; HIVþ, HIV-infected children; HUU, HIV-unexposed-uninfected children; IQR, interquartile range; PEC,
peripheral expanded cells; RTE, recent thymic emigrant cells.(18.6–39.4)% and 35.6 (26.2–42.6)%; P¼ 0.085]. The
percentages of senescent cells (CD4þCD28CD57þ)
were similar in the three groups, whereas activated
CD38þHLA-DRþ and exhausted PD-1þ were more
expanded in HIVþ children than in controls (Table 2). In
particular, within the HIVþ group, the percentages of
CD4þCD38þHLA-DRþ and CD4þPD-1þ were higher
in children with detectable viral load than in aviremic
children (P¼ 0.056 and P¼ 0.037, respectively).
The median of CD8þ cell percentages tended to be
higher in HIVþ children than in control groups
(P¼ 0.063). Notably, significant differences emerged
among CD8þ T-cell subsets. HIVþ children showed
lower percentage of naive cells than HEU and HUU
children [46.2 (37.6–75.1)%, 77.1 (55.9–84.7)%, 71.0
(46.7–86.1)%; P¼ 0.019]. In particular, HIVþ children
had a lower frequency of CD8þ recent thymic emigrant
[recent thymic emigrant cells (RTE), CD45RAþCD31þ)
cells (P¼ 0.005) and a higher percentage of peripheral
expanded cells [peripheral expanded cells (PEC)
CD45RAþCD31] than control groups (P¼ 0.040),
suggesting strong peripheral cell proliferation (Table 2). In
addition, the percentage of CD8þ RTE cells decreased
with age in HEU and HUU but not in HIVþ children
(Fig. 2a-c ). Interestingly, CD8þ RTE cells were lower in
children with detectable viral load than in aviremic
children [41.8 (22.6–64.4)% ‘vs.’ 55.9 (53.6–76.7)%;
P¼ 0.039] (not shown); plasma HIV-RNA tended to be
inversely correlated with CD8þ RTE cells (rs¼0.363,
P¼ 0.080) and positively correlated with CD8þ PEC
(rs¼ 0.357, P¼ 0.085) (Fig. 2d).
Among memory cell subsets, the frequency of CD8þ
central memory did not differ among HIVþ, HEU, and Copyright © 2016 Wolters Kluwer HHUU children (P¼ 0.278). However, in the HIVþ
group, this subset was more expanded in children with
detectable viremia than in those with undetectable HIV-
RNA (P¼ 0.027) (not shown). Both effector memory
(CD45RACD27) and terminally differentiated cells
(CD45RAþCD27) were more expanded in HIVþ
children than in control groups (Table 2). In HIVþ
children, the proportion of senescent CD8þ cells was also
higher than in HEU and HUU groups [25.8 (12.4–
43.2)% ‘vs.’ 8.5 (6.8–16.7)% and 9.7 (3.3–27.3)%;
P¼ 0.004]. This expansion was particularly observed in
children with detectable plasmaviremia, indicating that
active HIV replication stimulates the production of a
senescent phenotype [41.6 (18.5–45.8)% ‘vs.’ 4.4 (2.1–
13.4)%; P¼ 0.002]. In addition, the activation of CD8þ
cells was significantly higher in HIVþ children than in
controls [7.0 (5.2–12.2)% ‘vs.’ 4.7 (3.9–7.6)% in HEU
and 3.4 (2.8–6.7)% in HUU; P< 0.001] (Table 2), and
significantly increased with HIV-RNA levels (rs¼ 0.672;
P< 0.001) (not shown). The percentages of CD8þPD-
1þ cells were significantly higher in HIVþ than in HEU
and HUU children (P¼ 0.003 and P< 0.001, respect-
ively) (Table 2). After adjustments for multiple testing, the
CD4þ cell subset, and the CD8þ terminally differen-
tiated, activated, exhausted, senescent, and RTE cell
subsets remained significantly different (P< 0.05). Also,
the levels of proinflammatory cytokines IL-6 and TNFa
associated with the senescent phenotype [29–31] were
higher in HIVþ than in HEU and HUU children
(Supplementary Table 2, http://links.lww.com/QAD/
A905), thus supporting the accelerated immune senes-
cence in HIVþ children. PD-1 expression in viremic
subjects was also significantly higher than in those with
undetectable plasmaviremia (P¼ 0.002) and was corre-
lated with HIV-RNA levels (rs¼ 0.471, P¼ 0.021) andealth, Inc. All rights reserved.
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Fig. 2. Relationship between recent thymic emigrant (RTE) CD8R cells with age and HIV plasmaviremia. Percentage of CD8þ
RTE cells as function of age in (a) HUU, (b) HEU, and (c) HIVþ children. (d) Levels of HIV plasmaviremia in relation to percentages
of CD8þ RTE (black circles, continuous line) and CD8þ peripheral expanded cells (PEC) (white circles, dotted line) among HIVþ
children. rs, Spearman’s r correlation coefficient.CD8þCD38þHLA-DRþ cells (rs¼ 0.528, P¼ 0.009)
(not shown).
Telomere length values were inversely correlated with
percentages of senescent (Fig. 3a), activated (Fig. 3d) and
exhausted CD8þ cells (Fig. 3g) in HIVþ, but not in HEU
(Fig. 3b, e, h) or HUU children (Fig. 3c, f, i).
HIV-infected children have increased gut
microbial translocation
Median levels of sCD14 were significantly higher in
HIVþ than in HEU and HUU children [2699 (2333–
2826) ‘vs.’ 2138 (1954–2427) and 2065 (1850–2480)
ng/ml; P< 0.001] (Supplementary Figure 2A, http://
links.lww.com/QAD/A903). In HIVþ children, sCD14
levels positively correlated with HIV-RNA levels
(rs¼ 0.585, P¼ 0.007), with percentages of CD8þHLA-
DRþCD38þ (rs¼ 0.418, P¼ 0.065), and CD8þPD-1þ
(rs¼ 0.645, P¼ 0.002), but not with percentages of
CD8þCD28CD57þ (rs¼ 0.172, P¼ 0.487) or telomere
length (rs¼0.386, P¼ 0.124) (Supplementary Figure
2b-f, http://links.lww.com/QAD/A903). Copyright © 2016 Wolters KluweDiscussion
This is the first study describing biological aging and
immune senescence in HIV-infected children compared
with HIV-exposed-uninfected and unexposed-unin-
fected children, all aged 0–5 years. Overall, the results
demonstrate that HIV-infected children exhibit prema-
ture biological aging with accelerated immune senes-
cence which affects the CD8þ T-cell subset in particular.
In contrast to the study of Coˆte´ et al. [21], which found no
difference in telomere length between HIVþ children
and controls, in our study telomere length was
significantly shorter in HIVþ than in HEU and HUU
children. This discordant result may be because of the
different ages of the two cohorts: the children enrolled in
our study were younger (aged 0–5 years, median 3.1)
than those of Coˆte´ et al. (aged 0–19 years, median 13.3).
As telomere shortening in peripheral blood cells is very
rapid during the first years of life [32], the difference
between HIV-infected children and controls may have
emerged more clearly in our cohort. The two cohorts also
differed in duration of ART exposure. The longerr Health, Inc. All rights reserved.
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Fig. 3. Relationship between telomere length (TL) and T-cell immunophenotypic profiles. TL values in relation to percentages of
senescent (CD8þCD28CD57þ) cells in (a) HIVþ, (b) HEU, and (c) HUU children, activated (CD8þCD38þHLA-DRþ) cells in (d)
HIVþ, (e) HEU, and (f) HUU children, and exhausted (CD8þPD-1þ) cells in (g) HIVþ, (h) HEU, and (i) HUU children. HIVþ, HIV-
infected; HEU, HIV-exposed uninfected; HUU, HIV-unexposed uninfected; rs, Spearman’s r correlation coefficient.exposure to ARTof children in the above study (median
85 months of ART exposure) may explain the loss of
association found in our study population, consisting of
ART-naı¨ve children or ones recently on ART (median 18
months of ART exposure).
Nucleoside reverse transcriptase inhibitors are known
inhibitors of telomerase reverse transcriptase, and have
been reported to be associated with telomere shortening
[11,12]. The inverse association between telomere length
and ART-exposure (median time 123 months) has
recently been demonstrated in a cohort of adults, but
the small sample size and lack of optimal control of ART-
naive patients preclude definite conclusions [33]. Two
other studies of HIV-infected adults [34,35] confirm the
association of telomere length shortening with HIV
status, but not with relatively short ART exposure
(median times 58 and 48 months, respectively).
In our group of HIV-infected children, the ART-naive
ones, even though younger than those on ART, had Copyright © 2016 Wolters Kluwer Hsignificantly shorter telomeres than the latter. All these
findings indicate that HIV infection per se, rather than
exposure to therapy, influences the aging process. Also,
the finding that over 90% of HEU children had been
perinatally exposed to ARTand that their telomere length
did not differ from those of HUU children indicates that
relatively short-term ARTexposure does not significantly
influence telomere length, matching the results of a
recent report [36]. It is possible that longer exposure to
ART in HIV-infected children exacerbates HIV-driven
telomere shortening.
The mechanism behind telomere shortening in HIV-
infected individuals is unknown. Short telomeres may be
because of excessive cellular replication after chronic
immune activation, but the virus itself may play an active
role. Telomerase activity is in fact severely impaired in
uninfected CD34þ hematopoietic progenitor cells iso-
lated from HIV-infected patients [37]. HIV infection and
HIV-Tat protein also downmodulate telomerase expres-
sion and activity in lymphoblastoid cells [38] andealth, Inc. All rights reserved.
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CD4þ T cell is the target of HIV infection, we found
that CD8þ T-cell compartment was largely impaired in
the HIV-infected children. They had a lower frequency
of CD8þ naive cells than controls and a decline in this
cell subset did not correlate with age, as occurs in HIV-
uninfected children. In particular, the decreased
percentages of RTE cells with increased percentages
of PEC together with increasing levels of HIV
plasmaviremia indicate that HIV induces peripheral
proliferation of CD8þ cells and their differentiation
into effector cells, which play a central role in
immunity against pathogens [42]. As already described
in adults and older children [22,43,44], the decrease in
naive cell subset is associated with skewed maturation of
CD8þ cells toward an effector phenotype which,
without adequate replenishment of new CD8þ naive
cells, induces accumulation of cells with a senescent
phenotype. A major driver of the cellular senescent
phenotype is telomere shortening [29]. Our data
indicate that HIV-infected children accumulate
CD8þCD38þ and CD8þPD-1þ cells together with a
higher percentage of senescent CD8þ cells. The finding
that activated and exhausted CD8þ cells are inversely
correlated with telomere length supports the idea that
persistent immune activation and cellular exhaustion
are closely linked to accelerated biological aging and
immune senescence. Chronic viral coinfections may
induce immune activation and accelerate immune
senescence [35,45,46]. In particular, it has been shown
that cytomegalovirus (CMV) leads to significant
changes in the CD8þ repertoire [45,46]. Unfortunately,
clinical data on CMV serology were available only for
HIVþ and a subgroup of HEU children: 40 of 71
(56.3%) HIVþ and nine of 33 (27.3%) HEU children
were CMV-positive. The CMVþ and CMV sub-
groups of HIV-infected children did not significantly
differ as regards telomere length and markers of
immunological profile. Larger studies are needed to
better understand the contribution of coinfections in
the aging process of HIV-infected children.
The finding that sCD14 levels were correlated with
percentages of activated/exhausted CD8þ cells and the
lack of correlation between sCD14 and senescent CD8þ
cells and/or telomere length suggest that the gut damage
and gastrointestinal lymphocyte depletion which occurs
during HIV infection do not directly cause immune
senescence, but they do contribute to accelerated aging
and senescence through immune system activation.
Overall, our data support a scenario in which viremia
leads to high turnover with continual loss and output of
naı¨ve cells, which rapidly differentiate and exhaust their
effector function, resulting in an accumulation of
senescent cells with short telomeres. These data are
consistent with a previous report [47] showing that high
percentage of CD8þCD28 correlates with shorter
telomeres. Copyright © 2016 Wolters KluweThe evidence that immune senescence is more serious in
children with detectable HIV viremia focuses attention
on the need for early and long-standing control of HIV
replication and chronic immune activation. In particular,
this aspect must be considered when a treatment
interruption has been planned [48]. As previously
demonstrated in a pediatric cohort, viremia does impair
the immune reconstitution of memory and effector
CD4þ T-cell subsets [49], and also contributes to the
expansion of T-regulatory cells [50] which may influence
the specific HIV immune response, allowing the virus to
replicate and increase immune activation.
In conclusion, HIV-infected children exhibit premature
biological aging with accelerated immune senescence,
which particularly affects the CD8þ T-cell subset. The
shorter telomere length and higher percentage of
senescent cells in HIVþ children, compared with
children on ART or HEU, suggest that HIV infection
per se, rather than exposure to ART for prophylaxis or
treatment, influences the aging process. These data
support the importance of maintaining undetectable viral
load to avoid premature immune senescence and
dysfunction of CD8þ cells, compromising their tumor
immune surveillance function and increasing the risk of
age-related diseases, including malignancies.Acknowledgements
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